Detalhes bibliográficos
| Ano de defesa: |
2015 |
| Autor(a) principal: |
Peixoto, Fernanda Aparecida de Oliveira
 |
| Orientador(a): |
Costa, Paulo Sérgio Sucasas da
|
| Banca de defesa: |
Costa, Paulo Sérgio Sucasas da,
Beani, Lilian,
Costa, Lusmaia Damaceno Camargo,
Marques, Solomar Martins,
Naghettini, Alessandra Vitorino |
| Tipo de documento: |
Tese
|
| Tipo de acesso: |
Acesso aberto |
| Idioma: |
por |
| Instituição de defesa: |
Universidade Federal de Goiás
|
| Programa de Pós-Graduação: |
Programa de Pós-graduação em Ciências da Saúde (FM)
|
| Departamento: |
Faculdade de Medicina - FM (RG)
|
| País: |
Brasil
|
| Palavras-chave em Português: |
|
| Palavras-chave em Inglês: |
|
| Área do conhecimento CNPq: |
|
| Link de acesso: |
http://repositorio.bc.ufg.br/tede/handle/tede/7444
|
Resumo: |
Despite the improvement in survival of premature infants, there was no progress in the incidence of bronchopulmonary dysplasia, especially in the last 20 years. Systemic corticosteroids, which has always been a therapeutic option, fell into disuse because of its adverse effects on the neurological development of premature infants and other routes of admistration have been researched for use of corticosteroids. Budesonide, which is an inhaled steroid, has been studied in an attempt to prevent bronchopulmonary dysplasia. The objectives of this study were to determine if the intratracheal instillation of budesonide with surfactant, improved lung performance, prevents chronic lung disease and reduces mortality in premature infants with minimal adverse effects. This is a clinical trial, blind and randomized 90 preterm infants who required prophylaxis or early rescue therapy with surfactant: 45 were randomized in the treated group (0.25 mg/kg of budesonide and 100 mg/kg surfactant) and 45 in the control group (100 mg/kg of surfactant). The evaluated final outcomes were mortality and bronchopulmonary dysplasia. Although the treatment group has shown better results than the control group, in both cases, mortality (10x15) and bronchopulmonary dysplasia at 36 weeks corrected gestational age (8/35 x 10/32), there was no significant statistical difference (p = 0.501 and p = 0.571). No clinically significant adverse events were observed in the study. The study concludes that, despite not having been demonstrated statistically significant difference in your results, we can not rule out the benefits of budesonide instilled into the trachea through the surfactant. Other randomized and multicenter studies should be encouraged. |
